TRAX vs TVRD

First Tracks Biotherapeutics, I vs Tvardi Therapeutics, Inc. — Valuation Comparison 2026

TRAX

Pharmaceutical Preparations
First Tracks Biotherapeutics, I
Quality
1.7
out of 10
Value Trap
Price
$15.96
Last close
Models
7/13
Active
VS

TVRD

Pharmaceutical Preparations
Tvardi Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
32
LOW
Price
$3.38
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType TRAX Fair ValueTRAX Upside TVRD Fair ValueTVRD Upside
Bayesian DCF Intrinsic $4.26 -73.3% $2.17 -28.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.69 -76.9% $3.04 -3.1%
PWERM Option-Based $7.49 -53.0% $3.97 +26.4%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TRAX vs TVRD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TRAX vs TVRD — Which Stock Is More Undervalued?

TVRD scores higher with a 4.1/10 quality rating vs TRAX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing First Tracks Biotherapeutics, I (TRAX) and Tvardi Therapeutics, Inc. (TVRD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TRAX currently trades at $15.96 with a QOC of 1.7/10, while TVRD trades at $3.38 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).